Caris Quick Facts

  • Industry: Biotechnology, Biosciences
  • Service: Provides comprehensive tumor profiling for healthcare providers in over 50 countries worldwide
  • Headquarters: Irving, Texas, USA (Dallas-Fort Worth metroplex)
  • Employees: 300+
  • Product Names: Caris Molecular Intelligence® and ADAPT Biotargeting System™

Our Services

To fulfill its promise and to facilitate a deeper understanding of the biology of cancer and other complex diseases, Caris Life Sciences® has developed two patented and proprietary platforms. First, Caris Life Sciences pioneered a comprehensive, technology agnostic molecular testing offering to help physicians make more informed treatment decisions called Caris Molecular Intelligence® (CMI). CMI is the company’s proprietary and patented service offering, that provides oncologists with the most clinically actionable treatment options available to personalize cancer care today. To date, Caris has preformed more than 100,000 clinical cases using a variety of advanced profiling technologies to assess relevant biological changes in each patient’s tumor.

Caris Molecular Intelligence connects biomarker data generated from a tumor with biomarker-drug associations supported by evidence in the relevant clinical literature through a proprietary bioinformatics rules engine. Since 2009, Caris Life Sciences has tracked clinical and outcome data for certain patients undergoing tumor profiling, and has observed that patients treated with drugs consistent with their tumor profile show a significant increase in overall survival. As the industry leader, Caris provides reliable and actionable information about a patient’s tumor that serves as a molecular blueprint to personalize cancer therapy and improve care.

The company is also developing its ADAPT Biotargeting System™, a revolutionary platform for molecular characterization and targeting, with applications across therapy development, drug delivery, advanced diagnostics and disease monitoring. ADAPT uses the power of “next generation omics” to unlock systems biology. Currently being developed for cancer and other complex diseases, the ADAPT Biotargeting System is able to simultaneously measure millions of molecular interactions within complex biological systems in their natural state(s) – with the potential to impact the healthcare industry from pharmaceutical research to clinical diagnostics, and everything in between.

Our Industry Leadership

The management team is composed of a diverse group of leaders with experiences spanning business, finance, medical, scientific and technical services. Visit our management team page to view and download profiles.